SLN (Silence Therapeutics) Change In Inventory: $0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SLN Silence Therapeutics PLC SLN
45 GF Score
Price $10.50
GF Value $0.33
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Silence Therapeutics Change In Inventory?

Silence Therapeutics SLN +7.18% 45 Change In Inventory is $0.00 Mil as of Mar. 2026. GuruFocus rates SLN with a GF Score™ of 45/100 and a GF Value™ of $0.33 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Silence Therapeutics's change in inventory for the quarter that ended in Mar. 2026 was $0.00 Mil. It means Silence Therapeutics's inventory stayed the same from Dec. 2025 to Mar. 2026 .

Silence Therapeutics's change in inventory for the fiscal year that ended in Dec. 2025 was $0.00 Mil. It means Silence Therapeutics's inventory stayed the same from Dec. 2024 to Dec. 2025 .

Silence Therapeutics's Total Inventories for the quarter that ended in Mar. 2026 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Silence Therapeutics's Days Inventory for the quarter that ended in Mar. 2026 was 0.00.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Silence Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.00.

Silence Therapeutics  (NAS:SLN) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Silence Therapeutics's Days Inventory for the quarter that ended in is calculated as:

Days Inventory=Average Total Inventories/Cost of Goods Sold*Days in Period
=0/0.011*365 / 4
=0.00

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Silence Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2026 is calculated as

Inventory Turnover=Cost of Goods Sold / Average Total Inventories
=0.011 / 0
=N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Silence Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories / Revenue
=0 / 0.422
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Silence Therapeutics Change In Inventory Related Terms

Silence Therapeutics Change In Inventory Historical Data

* Premium members only.

The historical data trend for Silence Therapeutics's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Silence Therapeutics Change In Inventory Chart

Silence Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Inventory
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Silence Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Change In Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SLN
45GF Score
Silence Therapeutics PLC SLN
Change In Inventory is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Silence Therapeutics Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Inventory →
What does a Change In Inventory of $0.00 Mil mean?
Silence Therapeutics (SLN) has a Change In Inventory of $0.00 Mil as of Mar. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Silence Therapeutics and its competitors.
Is Silence Therapeutics' Change In Inventory too high?
Silence Therapeutics' current Change In Inventory is $0.00 Mil. Overall, Silence Therapeutics has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Silence Therapeutics' Change In Inventory compare to IMRX and VRXA?
Silence Therapeutics' Change In Inventory of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Biotechnology company?
A good Change In Inventory depends on the Biotechnology industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Silence Therapeutics and its competitors. Silence Therapeutics's current Change In Inventory is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Silence Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Silence Therapeutics (SLN) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.33, compared to a current price of $10.50 — trading 3081.8% above its estimated fair value. The current Change In Inventory is $0.00 Mil. Silence Therapeutics' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Silence Therapeutics (SLN), the current Change In Inventory is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Silence Therapeutics (SLN) Overvalued in 2026?

Based on GuruFocus' analysis, Silence Therapeutics stock appears to be overvalued. The current stock price of $10.50 is trading 3081.8% above its estimated GF Value™ of $0.33. GuruFocus considers Silence Therapeutics to be Significantly Overvalued.

Key valuation signals for SLN:

  • Change In Inventory: $0.00 Mil
  • GF Value™: $0.33 vs. price of $10.50 (3081.8% above fair value)
  • GF Score™: 45/100 with 5 warning signs

No single metric tells the full story. See the SLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Silence Therapeutics Business Description

Other Exchanges SLNCF:USAXRP2:Germany
Address 12 Hammersmith Grove, London, GBR, W6 7AP
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
45GF Score

Get the complete analysis for SLN

Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.50
Price
$0.33
GF Value